A message from our CEO & Chairman, Dr. Raphael Ribeiro-Pinaud: This Thanksgiving, I want to express my deepest gratitude for the incredible team at Antharis Therapeutics, Inc. and the shared purpose that drives us to push the boundaries of science and innovation, advancing therapies that have the potential to transform lives. Every breakthrough we pursue is fueled by our vision to bring optimism to patients and families affected by serious illness, and is made possible by the dedication and resilience of our exceptional group. I am humbled by the commitment and passion of everyone working toward a future where science brings hope to those who need it most. I also want to thank our partners, collaborators, and the patients who inspire us to aim higher every day. As I reflect on the progress we have made to date, and the impact and challenges ahead, I am reminded of the power of collective purpose. Wishing you and your loved ones a joyful and meaningful Thanksgiving, filled with gratitude, connection, and hope for the future.
Antharis Therapeutics, Inc.
生物技术
San Diego，CA 1,718 位关注者
Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge treatments for cancer.
关于我们
Antharis Therapeutics is a multinational biopharmaceutical company developing new treatments for cancer and inflammatory diseases. In particular, our company utilizes cutting-edge science to develop next-generation therapeutic monoclonal antibodies and antibody-drug conjugates with the end goal of treating unmet medical needs. The company, founded by Dr. Raphael R Pinaud in 2020, has significantly grown and successfully advanced its mission to date. Furthermore, Antharis strategically acquired Cassyni Biopharma and Galileo Biotech, in mid-2022 and mid-2023, respectively, to further and more effectively advance its mandate to bring transformational therapies to patients in need.
- 网站
-
https://www.antharistherapeutics.com
Antharis Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 私人持股
- 创立
- 2020
- 领域
- antibodies、therapies、antibody drug conjugates、therapeutic antibodies、monoclonal antibodies、neurology、cancer、oncology、cancer biology、biotechnology、biotech、pharmaceutical、biopharma、breast cancer、bispecific antibodies、pan cancer、colorectal cancer、brain cancer、lymphoma、leukemia和solid tumor
地点
Antharis Therapeutics, Inc.员工
-
Scott Maloney
Senior Partner at Crain | Investor | Independent Board Director | Turnaround Executive | Exits | Lucky Husband To One | Proud Father To Two
-
Daniel R. Yazbeck, M.Sc.
Head of Corporate Strategy | Antharis Therapeutics
-
Sareh S.
Scientist- Ph.D. "Cancer Biology"
-
Cass Morrison
Vice President of Operations at Antharis Therapeutics | US Army Veteran
动态
-
At Antharis Therapeutics, Inc., Lung Cancer Awareness Month is a time to reaffirm our commitment to advancing scientific innovation in the fight against this disease. Our team is dedicated to developing monoclonal antibody therapies, striving to bring next-generation solutions to patients impacted by this challenging disease. Every breakthrough in the lab drives progress, fosters hope and brings us closer to transforming outcomes for patients. Together, let’s raise awareness, support scientific innovation, and work toward a future where lung cancer is a thing of the past. #lungcancerawarenessmonth #fightingcancer #hopethroughscience #cancer #monoclonalantibody #ADC #biotherapeutics
-
-
We are excited to welcome Patric Nelson to the Antharis Therapeutics, Inc. team as our new Chief Business Officer! Patric brings a wealth of experience and a proven track record in driving business growth and fostering strong partnerships. His strategic mindset and leadership skills will be invaluable as we continue to expand our reach and deliver exceptional biotherapies to cancer patients in need. We look forward to Patric’s insights and contributions as he helps us navigate the next phase of our company’s journey. Welcome to the team, Patric! #WelcomeToTheTeam #Leadership #BusinessGrowth #Antharis #monoclonalantibodies #cancer #oncology #ADC #bispecificantibody #clinicaltrials
-
We are thrilled to welcome Daniel R. Yazbeck, M.Sc. as our new Head of Corporate Strategy. With a wealth of experience in strategic planning and business development, Daniel is set to play a pivotal role in driving growth and helping Antharis Therapeutics, Inc. achieve its long-term goals. His expertise and leadership will be instrumental as we continue to innovate and expand. We are excited to see how his vision and insights will shape our company’s future and look forward to the journey ahead. ?? #welcome #newteammember #corporatestrategy #growth #innovation #eadership #monoclonalantibody #biotherapeutics #oncology #cancer #antharis #antharistherapeutics #ADC #tumor #strategicalliances
Antharis Therapeutics Welcomes Daniel Yazbeck as Head of Corporate Strategy
antharistherapeutics.com
-
We are pleased to share a recent?Biotech Leader Spotlight?interview featuring our CEO and Chairman, Dr. Raphael R Pinaud, PhD, MBA. The interview highlights parts of his professional journey, as well as his remarkable vision, leadership and guidance of Antharis Therapeutics, Inc., which have been instrumental in driving our company’s many achievements until now. Under his stewardship, Antharis has made extraordinary strides in innovation, positioning itself as a forward-thinking company in the biotech sector. Congratulations Raphael! #monoclonalantibody #ADC #oncology #biotherapy #oncology #tumor #biotech #biotechexecutive #biotechleader #biotechnology #biopharma #pharma #pharmaceutical
In this weeks Biotech Leader Spotlight Series we're recognizing Raphael R Pinaud, PhD, MBA, Chief Executive Officer and Chairman of Antharis Therapeutics, Inc. Check out his interview to learn from his biopharma expertise spanning science, finance, business management, and regulatory affairs: Dr. Raphael Ribeiro-Pinaud is the Founder, CEO and Chairman of Antharis Therapeutics, where he has launched and grown the company to significant success, spearheaded M&A transactions with Cassyni Biopharma and Galileo Biotech, and expanded Antharis' asset portfolio and multinational presence. His expertise in the biotech/biopharma sector resides at the intersection of science, finance, business management and regulatory affairs. Before Antharis, he founded GB, a pioneering GMP-certified diagnostics company in Latin America, and served as a partner at Leste Global Investments, managing global biotech investments. Dr. Ribeiro-Pinaud has also held roles as an academic scientist and advisor to governmental health agencies. He holds a Ph.D. in Neuroscience from Oregon Health & Science University, completed postdoctoral work at Duke University in Bioengineering/Proteomics, earned an MBA in Economics and Business Management from FGV Business School in Brazil, and graduated from Harvard University’s Finance Leadership program. #biotech #biotechexecutive #biotechleader #biotechnology #biopharma #pharmaceuticals #CEO #drugdevelopment #therapeutics
Biotech Leader Spotlight Series
Partnology，发布于领英
-
Antharis is #hiring a Senior Scientist. Know anyone who would be interested? https://lnkd.in/gTVaF4Mr
Shape the Future with Antharis Therapeutics: Senior/Principal Scientist
antharistherapeutics.com
-
Antharis is #hiring. Know anyone who would be interested?
-
We are delighted with the recognition of our CEO & Chairman, Dr. Raphael R Pinaud, PhD, MBA, on the cover article of CIO Today, as one of the “Most Impactful CEOs of the Year 2024”. This article details Dr. Pinaud’s career trajectory, contributions to the field, as well as his unparalleled efforts and visionary leadership in propelling Antharis Therapeutics, Inc. towards excellence in the development of next-generation biotherapeutic medicines against unmet oncological diseases. This recognition further inspires our team to continue working to positively transform the lives of patients and families affected by devastating diseases. #cancer #antharis #monoclonalantibody #monoclonalantibodies #biotherapeutics #oncology #biotech #biopharma
-